SMS Pharma FY26 Revenue ₹886.87 Crore, Recommends 40% Dividend
SMS Pharmaceuticals Limited reported FY26 revenue of ₹886.87 crore and net profit of ₹87.61 crore (standalone). The company recommended a final dividend of 40% (₹0.40 per share). The registered office will be shifted effective May 25, 2026. Cost and Internal Auditors were appointed/re-appointed.
The financial results show growth, and the dividend recommendation is positive for shareholders. The shifting of the registered office is a minor corporate action.
The company reported increased revenue and profit for the fiscal year, and recommended a dividend, which are positive financial indicators.
SMS Pharmaceuticals Limited announced its audited financial results for the fourth quarter and full year ended March 31, 2026. The company's Board of Directors, in their meeting on May 22, 2026, approved the audited standalone and consolidated financial results.
The company reported a total income of ₹89,522.48 lakhs (₹886.87 crore) for the full financial year ended March 31, 2026, an increase from ₹78,897.25 lakhs (₹782.75 crore) in the previous year. Net profit after tax for the full year stood at ₹8,760.93 lakhs (₹87.61 crore) on a standalone basis and ₹8,799.79 lakhs (₹88.00 crore) on a consolidated basis.
The Board recommended a Final Dividend of ₹0.40 Paise (40%) per equity share of face value ₹1/- each for the financial year 2025-26, subject to the approval of the members at the ensuing Annual General Meeting (AGM).
Additionally, the company approved the shifting of its Registered Office within Hyderabad, effective from May 25, 2026. The Board also approved the appointment of M/s. Annapragada & Co. as Cost Auditors and the re-appointment of M/s. Adusumilli & Associates as Internal Auditors for the financial year 2026-27.
The auditors have issued an 'Unmodified Opinion' on the financial statements.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.